Hyperlipoproteinaemia(a) – apheresis and emerging therapies

Anja Vogt

Abstract A high level of lipoprotein(a) (Lp(a)) is recognized as an independent and additional cardiovascular risk factor contributing to the risk of early onset and progressive course of cardiovascular disease (CVD). All lipid lowering medications in use mainly lower low density lipoprotein-cholesterol (LDL-c) with no or limited effect on levels of Lp(a). Niacin, the only component lowering Lp(a), is firstly often poorly tolerated and secondly not available anymore in many countries. A level of <50 mg/dl was recommended recently as the cut off level for clinical use and decision making. Since lipoprotein apheresis (LA) lowers not only LDL-c but also Lp(a) significantly, its use is recommended in some countries in very high-risk patients with early or progressive CVD. Retrospective analyses show that regular LA improves the course of CVD. This is supported by a recent prospective observational trial and data of the German Lipoprotein Apheresis Registry. Despite many treatment options, all too often it is not possible to reduce LDL-c levels to target and to reduce Lp(a) levels sustainably at all. Therefore, new drug therapies are awaited. Some of the lipid modifying drugs in development lower Lp(a) to some extent in addition to LDL-c; the only specific approach is the apoprotein(a) antisense oligonucleotide. Currently LA is the standard of care as a last resort treatment in high-risk patients with elevated Lp(a) and severe CVD despite optimal control of all other cardiovascular risk factors.

Keywords Lipoprotein(a) · LDL-cholesterol · Apheresis · Atherosclerosis · New lipid-lowering therapies · Acute coronary syndrome

Introduction

Lipoprotein(a) (Lp(a)) in man was first described in 1963 by Berg, who stated that the level of Lp(a) is mainly inherited and that high levels of Lp(a) are associated with premature atherosclerosis [1]. This has been confirmed thereafter by observational data and supported in recent years by genetic data establishing Lp(a) as a causal factor for the development of atherosclerosis [2–8]. The European Guidelines on vascular disease prevention in clinical practice [9] mention high levels of Lp(a) as being associated with an increased risk of CVD and suggest to use levels of Lp(a) for risk stratification in individuals at moderate risk or with a positive family history of early CVD. The consensus paper of the European Atherosclerosis Society (EAS) [10] offers guidance. Lp(a) should be measured e.g. in all individuals at intermediate or high risk of CVD, in case of premature CVD, familial hypercholesterolaemia, premature CVD or high Lp(a) in the family, progressive CVD despite statin therapy.

Lp(a) consists of a low density lipoprotein (LDL) particle and an additional protein called apoprotein(a) (apo(a)), linked to apoprotein B (apoB) 100 of the LDL particle via one disulfide bond. Mostly the level depends on the size of apo(a) [11] and both are negatively correlated. The different laboratory methods are not comparable and results cannot be converted. If comparing data the used methods have to be taken into account. The consensus statement of the EAS recommended the use of an isofrom insensitive assay and suggested a level of <50 mg/dl as desirable [10]. Since risk
increases with increasing levels of Lp(a) and interventional data are missing, there is no established threshold.

**Established therapies**

**Drugs**

Some data show either a decrease or an increase of Lp(a) by statins [12], but mostly Lp(a) is not affected by statins [10, 13, 14] nor by ezetimibe [15]. Nicotinic acid (niacin) reduces Lp(a) besides positive effects on LDL-c, high density lipoprotein-cholesterol (HDL-c), and triglycerides [16]; high doses (2–4 g) reduce Lp(a) significantly [17]. Whether this holds true for individuals with high levels of Lp(a) has never been shown. A meta-analysis of the beneficial effects of nicotinic acid on cardiovascular events [18] did not discriminate whether the lowered levels of Lp(a) might have contributed to the positive results or not. It has to be mentioned that these data are mainly from the pre-statin era and would have to be confirmed in cohorts treated in line with current options and guidelines. In the EAS consensus paper niacin is recommended to reduce high levels of Lp(a) [10]. Since 2013 niacin is not available in Europe. In summary, no established drug treatment option to reduce Lp(a) is available at the moment.

**Lipoprotein apheresis**

Lipoprotein apheresis (LA) is in clinical use for over 30 years [19] and reduces apoB100 containing lipoproteins (namely LDL-c and Lp(a)). A single treatment reduces both by about 60–70%. The following increase is rapid [20]. For this reason, LA has to be repeated regularly and is done every week in most or every two weeks in some countries. Guidelines of several countries recommend LA in very high risk patients as a last resort therapy to lower LDL-c and maximal (tolerated) lipid lowering medication. Few countries also consider high levels of Lp(a) as an indication for LA in very high risk patients [21–24].

There are no randomised prospective trials. LA has beneficial effects regarding endothelial function and myocardial perfusion in patients with high levels of Lp(a) [25]. Retrospective evaluations of clinical data and analyses of the German Lipoprotein Apheresis Registry (GLAR) show that cardiovascular events were reduced significantly after establishing regular LA [26–28]. One retrospective evaluation indicates that patients with elevated Lp(a) irrespective of the LDL-c level have a greater benefit from LA than patients with low Lp(a) and high levels of LDL-c [29]. One prospective open-label trial used atorvastatin alone (control group). After 18 months a small but significant regression of coronary atherosclerosis was documented by angiography in the LA group [30]. The Pro(a)-LiFe-study, a non-randomised prospective observational multicentre study in high-risk patients, showed a reduction of major adverse cardiac events and of major adverse non-cardiac events after two [31] as well as after five years [32] of apheresis therapy.

Lipoprotein apheresis is well tolerated and safe in clinical use [24, 33] even for 2–3 decades of treatment. Several obstacles are opposed to a wide clinical use: it is time consuming, expensive, only offered in specialised centres, and mostly not covered by insurance companies.

**Emerging therapies**

In recent years several new lipid modifying approaches mostly addressing LDL-c were investigated. Inhibitors of the cholesterol ester transfer protein (CETP) increasing HDL-c and reducing LDL-c are not approved yet. In a phase-2 trial Anazetrapib additionally lowered Lp(a) by 50% [34]. In the REALIZE trial Anazetrapib showed a substantial reduction of Lp(a) by 31.8% in patients with heterozygous familial hypercholesterolaemia (FH) [35]. TA-8995, a newer agent, lowered Lp(a) in patients with dyslipidaemia by 36.9% (5 mg) and 33.4% (10 mg) at week 12 in a phase 2 trial [36]. The REVEAL trial using Anacetrapib to be published in 2017 will show whether this lipid modifying approach is beneficial in patients with established vascular disease [37].

The apoB antisense oligonucleotide (ASO) Mipomersen is approved in the US but not in Europe [38, 39]. Besides the reduction of LDL-c via less hepatic production of very low density lipoprotein (VLDL) Lp(a) is reduced by a still unclear mechanism. In a randomized trial Mipomersen [40] reduced initially elevated levels of Lp(a) significantly by 31.1%. In patients with heterozygous FH and coronary heart disease Mipomersen was added to lipid lowering therapy and reduced Lp(a) by 21.1% [41]. Thus, Mipomersen might reduce the necessity for lipoprotein apheresis in high-risk patients [42].

Lomitapide, an inhibitor of the microsomal triglyceride transfer protein (MTP), lowers LDL-c by reducing the assembly of VLDL in the liver as well of chylomicrons in the intestine. This is the only approach independent of the functionality of LDL-receptors. For this reason, the MTP-inhibitor Lomitapide significantly lowers LDL-c in homozygous FH (hoFH). Efficacy and safety in patients with hoFH were assessed in a single-arm, open-label, phase-3 study. Lp(a) was reduced by 19% at week 56 but at week 78 this was no longer seen [43]. Lomitapide is approved for hoFH.
PSCK9-inhibitors

Like the LDL-receptor the proprotein convertase subtilisin/kexin type 9 (PSCK9) is produced in the liver cells and released into the circulation. If PSCK9 is attached to the complex of LDL-receptor and LDL-c the receptor is degraded after internalisation and thus cannot be recycled for further uptake of LDL-c. Loss of function mutations come along with lower levels of LDL-c lifelong and are linked to a lower rate of cardiovascular events [44]. Two PSCK9-inhibitors (fully humanized monoclonal antibodies) to mimic these beneficial “natural” effects by binding PSCK9 and thus hampering the intracellular lysis of the LDL-receptor are approved. Overall, safety and tolerability profiles are very promising in both of the huge trial programmes. Long-term results show a sustained significant reduction of LDL-c [45, 46]. The LDL-c lowering effect is dependent on the functionality of the LDL-receptors and can vary wildly. Mean LDL-c reduction is about 50–60% and in some trials a lowering of Lp(a) [45–48] was seen as well (Evolocumab 25.5%, Alirocumab 30.2% [45]).

A pooled analysis [48] of three phase-2 Alirocumab trials specifically analysed the effect on Lp(a). Baseline levels between 2 and 181 mg/dl were parted in two groups (≤ and ≥50 mg/dl). In absolute values Lp(a) was reduced by 3.5 mg/dl and 27 mg/dl (mean), respectively, or relatively by 36% and 27% (median), respectively. In patients with LDL-receptor negative hoFH evolocumab was, as expected, ineffective in reducing LDL-c but all the same Lp(a) was lowered by 20% [49]. The upregulation of other receptors, e.g. the VLDL-receptor that mediates the uptake of Lp(a) into macrophages, might be an explanation for this finding. Some data show an increased catabolic fraction rate, others a reduced synthesis [50]. The development of bococizumab was terminated in November 2016 due to an unexpected decline of effectivity over time, a higher level of immunogenicity, and more frequent injection site reactions [51].

The results of the endpoint trials are expected in early 2017 (Evolocumab [52]) and in 2018 (Alirocumab [53]). Whether lowering Lp(a) by PSCK9-inhibitors contributes to the expected beneficial cardiovascular effects will have to be addressed in specifically designed trials.

Apo(a) antisense oligonucleotide

The ASO molecule IONIS-APO(a)-Rx specifically addresses the mRNA of apo(a). After a positive trial in transgenic mice [54] a phase-1 trial in healthy volunteers with Lp(a) levels ≥25 nmol/l was conducted. Various doses of the ASO lowered Lp(a) significantly (no relevant reduction of other lipoproteins). The highest dose of 300 mg reduced Lp(a) by 77.8%. This effect was sustained and Lp(a) was still lowered 84 days after the last dose [55].

Data of a phase-2 trial are awaited. If effectiveness and safety are shown this ASO would for the first time allow trials to address the question if the isolated lowering of high levels of Lp(a) results in lesser CVD.

Conclusion

The new drug developments will enable us to reduce LDL-c as significantly as never before with more high-risk patients reaching their treatment goals. The results of the endpoint trials will show to what extent this contributes to the expected reduction of cardiovascular events and deaths. The question if the concomitant lowering effect of Lp(a) is beneficial in addition has never been addressed so far. This will have to be evaluated in trials specifically addressing patients with high levels of Lp(a) and CVD. It is far more reasonable to address this question with the apo(a) ASO. So far, there are no data for any established or newly developed agent proving that the Lp(a) lowering effect is beneficial in high-risk cardiovascular patients.

All available data regarding lipoprotein apheresis, though not from RCTs, at least strongly support its beneficial effect of reducing cardiovascular events. In patients with controlled cardiovascular risk factors, LDL-c at goal, progressive cardiovascular disease, and markedly elevated levels of Lp(a) lipoprotein apheresis remains the only available and optimal care. As of today, it should be considered in high-risk patients wherever it is available.

Conflict of interest A. Vogt has received speakers’ honoraria for presentations and advisory board activities by Merck Sharp & Dohme, Genzyme, a Sanofi company, Kaneka, Fresenius, BBraun, Amgen, Regeneron, Sanofi. A. Vogt has received research support by Merck Sharp & Dohme.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Berg K (1963) A new serum type system in man – the Lp system. Acta Pathol Microbiol Scand 59:369–382
2. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlara S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M, Consortium P (2009) Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 361(26):2518–2528. doi:10.1056/NEJMoa0902604
3. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG (2014) Elevated lipoprotein(a) and risk of aortic valve stenosis in the general
population. J Am Coll Cardiol 63(5):470–477. doi:10.1016/j.jacc.2013.09.038
4. Kamstrup PR, Tybjærg-Hansen A, Steffensen R, Nordegaard B (2009) Genetically elevated lipoprotein(a) and increased risk of myocardi- al infarction. JAMA 301(22):2331–2339. doi:10.1001/jama.2009.801
5. Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, San- ter P, Oberhollenzer F, Egger G, Utterman G, Willeit J (1999) Role of lipoprotein(a) and apolipoprotein(a) phenotype in athero- genesis: prospective results from the Bruneck study. Circulation 100(11):1154–1160
6. Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M, Prib- asing A, Meisl T, Konig P, Dieplinger H (1999) The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective followup. J Am Soc Nephrol 10(5):1027–1036
7. Sandholzer C, Saha N, Kark JD, Rees A, Jarross W, Dieplinger H, Hop- pichler F, Boerwinkle E, Uttermann G (1992) Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb 12(10):1214–1226
8. Kraft HG, Lingenhel A, Kochl S, Hoppliecher F, Kronenberg F, Abe A, Mulheriger V, Schonitzer D, Uttermann G (1996) Apolipoprotein(a) kringel IV repeat number predicts risk for coronary heart disease. Arteriosclerosis Thromb Vasc Biol 16(1):713–719
9. Authors/Task Force M, Piepoli MF, Hoes AW, Agewall S, Albus C, Kraft HG, Lingenhel A, Kochl S, Hoppichler F, Utermann G (1992) Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb 12(10):1214–1226
10. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, Giebisch G, Amarencio P, Catapano A, Descamps OS, Fischer E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner T, Taskinen MR, Tokgozoglu L, Tybjærg-Hansen A (2010) Lipopro- tein(a) as a cardiovascular risk factor: current status. Eur Heart J 31(31):2844–2853. doi:10.1093/euheartj/ehq386
11. Uttermann G (1989) The mysteries of lipoprotein(a). Science 246(4932):904–910
12. Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgeuth J, Ridker PM, Mora S (2014) Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk; an analysis from the JUPITER trial (justification for the use of statins in preven- tion: an intervention trial evaluating rosuvastatin). Circulation 129(6):635–646. doi:10.1161/CIRCULATIONAHA.113.004406
13. Tirolf K, Ehrig Y, Wierzbicki AS, Mikhailidis DP (2009) Lipoprotein a: where are we now? Curr Opin Cardiol 24(4):351–357. doi:10.1097/HCO.0b013e3282aa21a
14. Kei A, Liberopoulos E, Tellis K, Rizzo M, Elisaf M, Tselapis A (2013) Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot study. Eur J Clin Invest 43(7):698–707. doi:10.1111/eci.12095
15. Moutzouri E, Liberopoulos EN, Tellis CC, Milionis HJ, Tselapis AD, Elisaf MS (2013) Comparison of the effect of simvastatin ver- sus simvastatin/ezetimibe versus rosuvastatin on markers of inflam- mation and oxidative stress in subjects with hypercholesterolemia. Atherosclerosis 231(1):8–14. doi:10.1016/j.atherosclerosis.2013.08.013
16. Carlson LA, Hamsten A, Asplund A (1989) Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid. J Intern Med 226(4):271–276
17. Goldberg A, Alagona P Jr., Capuzzi DM, Guyton J, Morgan JM, Rogers J, Sachson R, Samuel P (2000) Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 85(9):1100–1105. doi:10.1006/jcard.2000.8011
18. Bruckert E, Labreuche J, Amarenco P (2010) Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascu- lar events and atherosclerosis. Atherosclerosis 210(2):353–361. doi:10.1016/j.atherosclerosis.2009.12.023
19. Abel J (1914) Plasma removal with return of corpuscles. J Pharma- col Exp Ther 5(6):625–641
20. Thompson GR (2010) Lipoprotein apheresis. Curr Opin Lipidol 21(6):487–491. doi:10.1097/MOL.0b013e32836e13
21. Bundesausschuss G (2010) Richtlinie des Gemeinsamen Bunde- sausschusses zu Untersuchungs- und Behandlungsmethoden der vertragsärztlichen Versorgung. Bundesanze 109:2561
22. Derfler K, Steiner S, Sizinier H (2015) Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment. Wien Klin Wochenschr 127(15–16):655–663. doi:10.1007/s00080-015-0833-4
23. Stefano C (2010) The 2009 2nd Italian Consensus Conference on LDL-apheresis. Nutr Metab Cardiovasc Dis 20(10):761–762. doi:10.1016/j.numecd.2010.04.007
24. Thompson GR (2008) Recommendations for the use of LDL apheresis. Atherosclerosis 198(2):247–255. doi:10.1016/j.ath- erosclerosis.2008.02.009
25. Bohl S, Kassner U, Eckardt U, Utz W, Mueller-Nordhorn J, Bus- jscha J, Thomas HP, Abdel-Aty H, Klingel R, Marcovina S, Di- etz R, Steinhaagen-Thiessen E, Schulz-Menger J, Vogt A (2009) Single lipoprotein apheresis session improves cardiac microvascular function in patients with elevated lipoprotein(a): detection by stress/rest perfusion magnetic resonance imaging. Ther Apher Dial 13(2):129–137. doi:10.1111/j.1744-9987.2009.00667.x
26. Jaffer BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, Parhofer K, Ramlow W, Koch M, Uttermann G, Labarrere CA, Parhofer K, Ramlow W, Koch M, Uttermann G, Labarrere CA, Seidel D, Group of (2009) Longitudinal cohort study on the effec- tiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 6(3):229–239. doi:10.1038/ncpcardio1456
27. Rosada A, Kassner U, Vogt A, Willhauck M, Parhofer K, Stein- haagen-Thiessen E (2014) Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events? Artif Organs 38(2):135–141. doi:10.1111/ aor.12135
28. Schettler VJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roe- seler K, Ramlow W, Koch M, Uttermann G, Labarrere CA, Seidel D, Group of (2009) Longitudinal cohort study on the effectiv- eness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 6(3):229–239. doi:10.1038/nccardio1456
29. von Dryander M, Fischer S, Passauer J, Muller G, Bornstein SR, Rodgers J, Sachson R, Samuel P (2000) Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 85(9):1100–1105. doi:10.1006/jcard.2000.8011
30. Safarova MS, Ezhov MV, Anasizheva OL, Matchin YG, Atanesyan RV, Adamova IY, Utkina EA, Konovalov GA, Pokrovsky SN (2013) Effect of specific lipoprotein(a) apheresis on coronary atheroscle- rosis regression assessed by quantitative coronary angiography.
Atheroscler Suppl 14(1):93–99. doi:10.1016/j.atherosclerosissup.2012.10.015

31. Leebmann J, Roeseler E, Julius U, Heigl F, Spithoever R, Heutling D, Breitenberger P, Maerz W, Lehmacher W, Heibges A, Klingel R. ProLifE Study G (2013) Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 128(24):2567–2576. doi:10.1161/CIRCULATIONAHA.113.002432

32. Roeseler E, Julius U, Heigl F, Spithoever R, Heutling D, Breitenberger P, Leebmann J, Lehmacher W, Kamstrup PR, Nordsetgaard BG, Maerz W, Naureen A, Schmidt K, Kronenberg F, Heibges A, Klingel R. ProLifE-Study G (2016) Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization. Atheroscler Thromb Vasc Biol 36(9):2019–2027. doi:10.1161/ATVBBAHA.116.307983

33. Thompson GR, Lowenthal R, Myant NB (1975) Plasma exchange therapy in the management of homozygous familial hypercholesterolaemia. Lancet 1(7918):1208–1211. doi:10.1016/s0140-6736(75)92193-5

34. Thompson GR, Lowenthal R, Myant NB (1975) Plasma exchange therapy in the management of homozygous familial hypercholesterolaemia: results of a randomized, double-blind, placebo-controlled trial. Lancet 385(9983):2153–2161. doi:10.1016/s0140-6736(14)62115-2

35. Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Hovingh GK, Al-Saady N, Koeijvoets M, Hunter J, Johnson-Levonas AO, Fable J, Sapre A, Mitchell Y (2015) Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled phase 3 study. Lancet 385(9992):2135–2161. doi:10.1016/S0140-6736(14)62115-2

36. Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, Rader DJ, Brewer HB, Barter PJ (2015) Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled trial phase 2 trial. Lancet 386(9992):452–460. doi:10.1016/S0140-6736(15)60158-1

37. Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL). https://clinicaltrials.gov/ct2/show/NCT01252953

38. Rader DJ, Kastelein JJ (2014) Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolaemia. Circulation 129(9):1022–1032. doi:10.1161/CIRCULATIONAHA.113.001292

39. Parhofer KG (2012) Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia. Core Evid 7:29–38. doi:10.2147/CE. S25239ce-7-029

40. Raal FJ, Santos RD, Blom DJ, Marais AD, Chang MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flain JD, Crooke ST (2010) Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375(9719):998–1006. doi:10.1016/S0140-6736(10)60284-X

41. Stein EA, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, Chin W, Tribble DL, McGowan M (2012) Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 126(19):2283–2292. doi:10.1161/CIRCULATIONAHA.112.104125

42. Vogt A, Parhofer KG (2013) The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease. Expert Opin Pharmacother 14(6):691–697. doi:10.1517/14656566.2013.779253

43. Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, Averna MR, Sirtori CR, Shah PK, Gaudet D, Stefani C, Vigna GB, Du Plessis AM, Propert KJ, Sasiela WJ, Bloedon LT, Rader DJ, Phase 3 Ho FHLSi (2013) Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolemia: a single-arm, open-label, phase 3 study. Lancet 381(9860):40–46. doi:10.1016/S0140-6736(12)61731-0

44. Cohen JC, Boerwinkle E, Mosley TH Jr., Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354(12):1264–1272. doi:10.1056/NEJMoA054013

45. Robinson JG, Farnier M, Krempl M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Ral FJ, Shahawey ME, Koresen MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ, Investigators OL (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. doi:10.1056/NEJMoA1500855

46. Sabatine MS, Giugliano RP, Wiviott SD, Ral FJ, Blom DJ, Robinson JG, Ballantyne CM, Somarathne R, Legg J, Wasserman SM, Scott R, Koresen MJ, Stein EA, Open-Label Study of Long-Term Evaluation against LDLCl (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. doi:10.1056/NEJMoA1501031

47. Raal FJ, Giugliano RP, Sabatine MS, Koresen MJ, Langslet G, Bays H, Blom D, Eriksson M, Dent R, Wasserman SM, Huang F, Xue A, Albizem M, Scott R, Stein EA (2014) Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 63(13):1278–1288. doi:10.1016/j.jacc.2014.01.006

48. Gaudet D, Kereiakes DJ, Mc Kenney JM, Roth EM, Hanotin C, Gipe D, Y, Ferrand AC, Ginsberg BN, Stein EA (2014) Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of more than 150mg every two weeks dosing from phase 2 trials). Am J Cardiol 114(5):711–715. doi:10.1016/j.amjcard.2014.05.060

49. Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein IA, Investigators T (2015) Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 385(9965):341–350. doi:10.1016/S0140-6736(14)61374-X

50. Desai NR, Kohli P, Giugliano RP, O’Donoghue ML, Somarathne R, Zhou J, Hoffman EB, Huang F, Rogers WJ, Wasserman SM, Scott R, Sabatine MS (2013) AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150mg every two weeks dosing from phase 2 trials). Am J Cardiol 114(5):711–715. doi:10.1016/j.amjcard.2014.05.060

51. Pfister (2016) Pfizer discontinues global development of bococizumab, its investigational PCSK9 inhibitor. Pfizer, New York

52. Sabatine MS, Giugliano RP, Keech A, Honarpour N, Wang H, Liu T, Wasserman SM, Scott R, Sever PS, Pedersen TR (2016) Rationale and design of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk trial. Am Heart J 173:94–101. doi:10.1016/j.ahj.2015.11.015
53. Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shiodaria C, Szarek M, Tambly JF, Tricoci P, White H, Zeiher A, Steg PG (2014) Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J 168(5):682–689. doi:10.1016/j.ahj.2014.07.028

54. Merki E, Graham M, Taleb A, Leibundgut G, Yang X, Miller ER, Fu W, Mullick AE, Lee R, Willeit P, Crooke RM, Witztum JL, Tsimikas S (2011) Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J Am Coll Cardiol 57(15):1611–1621. doi:10.1016/j.jacc.2010.10.052

55. Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, Burkey JL, Yang Q, Marcovina SM, Geary RS, Crooke RM, Witztum JL (2015) Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 386(10002):1472–1483. doi:10.1016/S0140-6736(15)61252-1